Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of P-Nitrophenylphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.57 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.56 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.67 |
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Nitrophenylphosphate SCHEMBL168768 | 0.98 | CA1 (0.69) | CA1CA2CES2CES1ACHE | |
| P-Nitrophenylphosphate SCHEMBL11322617 | 0.96 | CA1 (0.67) | CA1CA2CES2CES1ACHE | |
| P-Nitrophenylphosphate SCHEMBL30776755 | 0.96 | CA1 (0.67) | CA1CA2CES2CES1ACHE | |
| P-Nitrophenylphosphate SCHEMBL11103558 | 0.96 | CA1 (0.67) | CA1CA2CES2CES1ACHE | |
| P-Nitrophenylphosphate SCHEMBL11104501 | 0.96 | CA1 (0.67) | CA1CA2CES2CES1ACHE | |
| P-Nitrophenylphosphate SCHEMBL11322610 | 0.96 | CA1 (0.67) | CA1CA2CES2CES1ACHE | |
| SCHEMBL4609079 | 0.88 | CA1 (0.67) | CA1CA2CES2CES1ACHE | |
| P-Nitrophenylphosphate SCHEMBL29163719 | 0.85 | CA1 (0.54) | CA1CA2CES2CES1ACHE | |
| P-Nitrophenylphosphate SCHEMBL6681723 | 0.85 | CA1 (0.73) | CA1CA2CES2CES1ACHE | |
| SCHEMBL11588707 | 0.84 | CA1 (0.67) | CA1CA2CES2CES1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113758909-A | Detection method of alkaline phosphatase | 长江大学 | 2021-12-07 | — | — | CN | claimed |
| CN-111579625-A | Electron donor co-regulation self-powered photoinduced electrochemical method | 青岛科技大学 | 2020-08-25 | — | — | CN | claimed |
| US-12534519-B2 | Molecules for therapy and diagnosis | AC IMMUNE SA (CH) | 2026-01-27 | — | — | US | disclosed |
| US-12486319-B2 | Anti-tau antibodies and methods of use | AC IMMUNE SA (CH) | 2025-12-02 | — | — | US | disclosed |
| US-20250340623-A1 | Novel Molecules for Therapy and Diagnosis | AC IMMUNE SA (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250320283-A1 | Antibodies Binding to Alpha-Synuclein for Therapy and Diagnosis | AC IMMUNE SA (CH) | 2025-10-16 | — | — | US | disclosed |
| EP-4628527-A2 | LIPOPOLYSACCHARIDE PRODUCTION METHOD | Biomedical Research Group Inc. (JP) | 2025-10-08 | — | — | EP | disclosed |
| EP-4623078-A1 | TRIGGER-INDUCIBLE MRNA CIRCULARIZATION | Westlake University (CN) | 2025-10-01 | — | — | EP | disclosed |
| EP-4036245-B1 | LIPOPOLYSACCHARIDE PRODUCTION METHOD | BIOMEDICAL RES GROUP INC (JP) | 2025-06-11 | — | — | EP | disclosed |
| CN-119868696-A | Blood treatment device comprising alkaline phosphatase | 甘布罗伦迪亚股份公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-116008557-B | Method for detecting active soluble urokinase receptor and detection kit | 福建亿彤生物科技有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-0792157-A1 | PREPARATION OF MHC-PEPTIDE COMPLEXES | ANERGEN, INC. (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5622837-A | REACTS WITH BODY FLUID AND STOOLS | SCHEBO TECH MEDIZINISCH-BIOLOGISCHE FORSCHUNGSGESELLSCHAFT MBH (DE) | 1997-04-22 | — | — | US | disclosed |
| WO-1996027016-A1 | METHODS AND COMPOSITIONS FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES | GENENTECH, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1996010415-A9 | PREPARATION OF MHC-PEPTIDE COMPLEXES | — | 1996-06-20 | — | — | WO | disclosed |
| WO-1996010415-A1 | PREPARATION OF MHC-PEPTIDE COMPLEXES | ANERGEN, INC. (US) | 1996-04-11 | — | — | WO | disclosed |
| EP-0547059-B1 | PANCREAS-ELASTASIS-1-SPECIFIC ANTIBODY, A PROCESS FOR OBTAINING IT AND A TEST KIT CONTAINING SUCH ANTIBODIES | SCHEBO TECH MEDIZINISCH BIOLOG (DE) | 1995-10-04 | — | — | EP | disclosed |
| EP-0444118-B1 | PYRUVATE-KINASE-ISOENZYME-TYPE-M2 (TUMOUR M2-PK) SPECIFIC ANTIBODIES, PROCESS FOR PRODUCING THEM AND USE | SCHEBO TECH MEDIZINISCH BIOLOG (DE) | 1994-06-29 | — | — | EP | disclosed |
| EP-0444118-A1 | PYRUVATE-KINASE-ISOENZYME-TYPE-M2 (TUMOUR M2-PK) SPECIFIC ANTIBODIES, PROCESS FOR PRODUCING THEM AND USE. | SCHEBO TECH MEDIZINISCH BIOLOG (DE) | 1991-09-04 | — | — | EP | disclosed |
| WO-1990005917-A1 | PYRUVATE-KINASE-ISOENZYME-TYPE-M2 (TUMOUR M2-PK) SPECIFIC ANTIBODIES, PROCESS FOR PRODUCING THEM AND USE | SCHEBO TECH MEDIZINISCH-BIOLOGISCHE FORSCHUNGSGESELLSCHAFT M.B.H. (DE) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534519-B2 | Molecules for therapy and diagnosis | SNCA, CDR2, IGSF11 | ACHE 3631/4885THRB 2502/4885MEN1 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.